Moderna Recursion: Which Cutting-Edge Path Is Best in 2026
Two biotech powerhouses take very different routes: Moderna builds medicines with mRNA, while Recursion uses machine ...
Learn about no annual fee credit cards that allow you to earn points. Start benefiting from your spending today!
25,023 articlesTwo biotech powerhouses take very different routes: Moderna builds medicines with mRNA, while Recursion uses machine ...
When bond yields spiking higher, stock prices can face pressure, especially for growth-focused names. This guide brea...
As AI data centers demand more power, nuclear options like NuScale Power and Constellation Energy rise in relevance. ...
Coca-Cola and PepsiCo enter 2026 with long dividend histories, but their cash flow realities diverge. This analysis w...
The FBI raised a terrorism alert Saturday as U.S.-led strikes on Iran sparked regional retaliation possibilities. Mar...
Investors watched iperionx limited stock crashed today after weak half-year results. This in-depth look breaks down t...
U.S. consumer discretionary stocks rise as demand improves in March 2026. Analysts cite pricing power and resilient c...
Investors woke up to news that rocket stock dropped today, sending shares of Rocket Lab into the spotlight. This arti...
Markets brace for Kevin Warsh's first Fed meeting amid stubborn inflation and political scrutiny. Observers ask wheth...
The U.S. government has imposed export controls on Anthropic’s Fable and Mythos, effectively creating a licensing reg...
After a two-week export-control standoff, Anthropic’s most powerful AI models are back online. The settlement restore...
A once-overlooked dividend ETF is delivering double-digit gains this year, signaling a shift from megacap leadership ...